| Title |
A single-dose placebo- and moxifloxacin-controlled study of the effects of temsirolimus on cardiac repolarization in healthy adults
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, February 2012
|
| DOI | 10.1007/s00280-012-1845-7 |
| Pubmed ID | |
| Authors |
Joseph P. Boni, Cathie Leister, Bruce Hug, Jaime Burns, Daryl Sonnichsen |
| Abstract |
Temsirolimus, a selective inhibitor of mammalian target of rapamycin, is an approved treatment for patients with advanced renal cell carcinoma (RCC). This study assessed the effect of intravenous (i.v.) temsirolimus 25 mg, the recommended dose for patients with RCC, on the corrected QT (QTc) interval. |
Mendeley readers
The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 19 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 4 | 21% |
| Student > Master | 4 | 21% |
| Student > Doctoral Student | 2 | 11% |
| Student > Ph. D. Student | 2 | 11% |
| Professor | 1 | 5% |
| Other | 2 | 11% |
| Unknown | 4 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 42% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 11% |
| Agricultural and Biological Sciences | 2 | 11% |
| Mathematics | 1 | 5% |
| Biochemistry, Genetics and Molecular Biology | 1 | 5% |
| Other | 1 | 5% |
| Unknown | 4 | 21% |